These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 21302642)

  • 1. Pharmacological therapy of neuroendocrine tumors.
    Rinke A; Ricci S; Bajetta E; Jelic S
    Tumori; 2010; 96(5):847-57. PubMed ID: 21302642
    [No Abstract]   [Full Text] [Related]  

  • 2. [Biotherapy of neuroendocrine tumours of the gastrointestinal tract and pancreas].
    Hansen CP; Knigge U
    Ugeskr Laeger; 2008 Jun; 170(24):2145-8. PubMed ID: 18565299
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hematological toxicity of combined 177Lu-octreotate radiopeptide chemotherapy of gastroenteropancreatic neuroendocrine tumors in long-term follow-up.
    Kesavan M; Claringbold PG; Turner JH
    Neuroendocrinology; 2014; 99(2):108-17. PubMed ID: 24714208
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination therapy with octreotide and alpha-interferon: effect on tumor growth in metastatic endocrine gastroenteropancreatic tumors.
    Frank M; Klose KJ; Wied M; Ishaque N; Schade-Brittinger C; Arnold R
    Am J Gastroenterol; 1999 May; 94(5):1381-7. PubMed ID: 10235222
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of capecitabine in the management of tumors of the digestive system.
    Gennatas C; Michalaki V; Gennatas S
    Rev Recent Clin Trials; 2009 Jan; 4(1):1-11. PubMed ID: 19149758
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Octreotide long-acting repeatable use among elderly patients with carcinoid syndrome and survival outcomes: a population-based analysis.
    Shen C; Shih YC; Xu Y; Yao JC
    Cancer; 2014 Jul; 120(13):2039-49. PubMed ID: 24676892
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Are capecitabine and oxaliplatin (XELOX) suitable treatments for progressing low-grade and high-grade neuroendocrine tumours?
    Bajetta E; Catena L; Procopio G; De Dosso S; Bichisao E; Ferrari L; Martinetti A; Platania M; Verzoni E; Formisano B; Bajetta R
    Cancer Chemother Pharmacol; 2007 Apr; 59(5):637-42. PubMed ID: 16937105
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of octreotide long-acting repeatable in neuroendocrine tumors: RADIANT-2 placebo arm post hoc analysis.
    Strosberg JR; Yao JC; Bajetta E; Aout M; Bakker B; Hainsworth JD; Ruszniewski PB; Van Cutsem E; Öberg K; Pavel ME
    Endocr Relat Cancer; 2015 Dec; 22(6):933-40. PubMed ID: 26373569
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Capecitabine and oxaliplatin for advanced esophagogastric cancer.
    Cunningham D; Okines AF; Ashley S
    N Engl J Med; 2010 Mar; 362(9):858-9. PubMed ID: 20200397
    [No Abstract]   [Full Text] [Related]  

  • 10. A phase II study of oxaliplatin, 5-fluorouracil, leucovorin, and high-dose capecitabine in patients with metastatic colorectal cancer.
    Lubner SJ; Loconte NK; Holen KD; Schelman W; Thomas JP; Jumonville A; Eickhoff JC; Seo S; Mulkerin DL
    Clin Colorectal Cancer; 2010 Jul; 9(3):157-61. PubMed ID: 20643620
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neoadjuvant 5-FU or Capecitabine Plus Radiation With or Without Oxaliplatin in Rectal Cancer Patients: A Phase III Randomized Clinical Trial.
    Allegra CJ; Yothers G; O'Connell MJ; Beart RW; Wozniak TF; Pitot HC; Shields AF; Landry JC; Ryan DP; Arora A; Evans LS; Bahary N; Soori G; Eakle JF; Robertson JM; Moore DF; Mullane MR; Marchello BT; Ward PJ; Sharif S; Roh MS; Wolmark N
    J Natl Cancer Inst; 2015 Nov; 107(11):. PubMed ID: 26374429
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II study of capecitabine and oxaliplatin for advanced adenocarcinoma of the small bowel and ampulla of Vater.
    Overman MJ; Varadhachary GR; Kopetz S; Adinin R; Lin E; Morris JS; Eng C; Abbruzzese JL; Wolff RA
    J Clin Oncol; 2009 Jun; 27(16):2598-603. PubMed ID: 19164203
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I-II study of radiopeptide 177Lu-octreotate in combination with capecitabine and temozolomide in advanced low-grade neuroendocrine tumors.
    Claringbold PG; Price RA; Turner JH
    Cancer Biother Radiopharm; 2012 Nov; 27(9):561-9. PubMed ID: 23078020
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Should capecitabine replace infusional fluorouracil and leucovorin when combined with oxaliplatin in metastatic colorectal cancer?
    Mayer RJ
    J Clin Oncol; 2007 Sep; 25(27):4165-7. PubMed ID: 17709796
    [No Abstract]   [Full Text] [Related]  

  • 15. Capecitabine and oxaliplatin for advanced esophagogastric cancer.
    Cunningham D; Starling N; Rao S; Iveson T; Nicolson M; Coxon F; Middleton G; Daniel F; Oates J; Norman AR;
    N Engl J Med; 2008 Jan; 358(1):36-46. PubMed ID: 18172173
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Radiosensitizing drugs: lessons to be learned from the oxaliplatin story.
    Flatmark K; Ree AH
    J Clin Oncol; 2010 Oct; 28(29):e577-8; author reply e581-3. PubMed ID: 20733124
    [No Abstract]   [Full Text] [Related]  

  • 17. Alternating systemic and hepatic artery infusion therapy for resected liver metastases from colorectal cancer: a North Central Cancer Treatment Group (NCCTG)/ National Surgical Adjuvant Breast and Bowel Project (NSABP) phase II intergroup trial, N9945/CI-66.
    Alberts SR; Roh MS; Mahoney MR; O'Connell MJ; Nagorney DM; Wagman L; Smyrk TC; Weiland TL; Lai LL; Schwarz RE; Molina R; Dentchev T; Bolton JS
    J Clin Oncol; 2010 Feb; 28(5):853-8. PubMed ID: 20048179
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasma disposition of capecitabine (CCB) and its metabolites 5'-deoxy-5-fluorocytidine (5'-DFCR) and 5'-deoxy-5-fluorouracil (5'-DFUR) with two different capecitabine/oxaliplatin dosage regimens.
    Farkouh A; Schueller J; Scheithauer W; Czejka M
    Int J Clin Pharmacol Ther; 2010 Jul; 48(7):487-8. PubMed ID: 20557855
    [No Abstract]   [Full Text] [Related]  

  • 19. A retrospective study of capecitabine/temozolomide (CAPTEM) regimen in the treatment of metastatic pancreatic neuroendocrine tumors (pNETs) after failing previous therapy.
    Saif MW; Kaley K; Brennan M; Garcon MC; Rodriguez G; Rodriguez T
    JOP; 2013 Sep; 14(5):498-501. PubMed ID: 24018594
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adjuvant therapy in colon cancer: which treatment in 2005?
    Di Costanzo F; Doni L
    Ann Oncol; 2005 May; 16 Suppl 4():iv69-73. PubMed ID: 15923433
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.